Trial Profile
A Controlled, Randomized, Parallel, Multicentre Study to Assess Safety and Tolerability of the Oral Direct Thrombin Inhibitor AZD0837, Given as an Extended-Release Formulation, in the Prevention of Stroke and Systemic Embolic Events in Patients With Atrial Fibrillation.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs AZD 0837 (Primary) ; Warfarin
- Indications Embolism; Stroke; Thromboembolism
- Focus Adverse reactions; Pharmacodynamics; Pharmacogenomic
- Sponsors AstraZeneca
- 01 Dec 2009 Results published in European Heart Journal.
- 29 Aug 2009 Results presented at the Annual Congress of the European Society of Cardiology (ESC-2009)
- 31 Mar 2009 Results were presented at the 58th Annual Scientific Session of the American College of Cardiology.